<DOC>
	<DOC>NCT00408434</DOC>
	<brief_summary>An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 patients with advanced or metastatic malignancies.</brief_summary>
	<brief_title>Study of an Experimental New Drug, PPAR Agonist Taken by Mouth by Patients With Advanced or Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Efatutazone</mesh_term>
	<criteria>Histologically or cytologically diagnosed advanced or metastatic malignancy that is refractory to, not curable with, or not eligible for standard treatment(s). 18 years or older ECOG performance status less than or equal to 2. Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE v3.0 grade less than or equal to 1. Adequate organ and bone marrow function. Willing to use effective contraceptive while on treatment through at least 3 months thereafter. Negative pregnancy test for females of childbearing potential. Echocardiogram with EF within normal range. Anticipation of need for a major surgical procedure or radiation therapy during the study. Treatment with chemotherapy, hormonal therapy, other TZDs, radiotherapy, minor surgery, or any investigational agent within 4 wks (6 wks for nitrosoureas, mitomycin C, immunotherapy, biological therapy, or major surgery) of study treatment start. Patients with clinically significant pleural or pericardial effusion (patients with minimal pleural effusion may be eligible at the Investigator's discretion). Clinically significant active infection, which requires antibiotic therapy, or HIVpositive patients receiving antiretroviral therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>PPARgamma agonist</keyword>
	<keyword>advanced or metastatic malignancies</keyword>
	<keyword>Tumor</keyword>
	<keyword>Cancer</keyword>
</DOC>